We have been greeted with good news of late — two vaccines, both built on an mRNA model, meaning an engineered solution rather than a dead vaccine model — will apply shortly for an Emergency Use Authorization from the Food and Drug Agency based on the successful completion of Phase 3, large scale (44,000 persons) trials and the attendant data with both showing an efficacy rate of 95%.
Efficacy rates, Big Red Car?
To put that 95% number into perspective, know that the common flu vaccine has an efficacy rate of 40-60% — meaning it shelters 40-60% of Americans who receive the shot from the flu.
So, the 95% efficacy rate for the engineered model is quite extraordinary.
American health officials required a 50% efficacy rate, had hoped for 60-70%, and are deliriously happy at 95%.